2023 World Conference on Lung Cancer (Posters)-EP11.03. Real World Experience of First Line Pembrolizumab for Non-Small Cell Lung Cancer (NSCLC) at a Tertiary Centre

EP11.03. Real World Experience of First Line Pembrolizumab for Non-Small Cell Lung Cancer (NSCLC) at a Tertiary Centre - PDF(Abstract)

Back to course

Pdf Summary

This study aimed to assess the real-world experience of using first-line pembrolizumab for the treatment of non-small cell lung cancer (NSCLC) at a tertiary center. The researchers also examined the association between pretreatment lung immune prognostic index (LIPI) and survival outcomes. The study included 55 patients with NSCLC who were treated with pembrolizumab between January 2016 and March 2023. The median age of the patients was 70, with 56% being male. The majority of patients had non-squamous histology and a PD-L1 tumor proportion score (TPS) of 50%. After a median follow-up of 26.2 months, 62% of the patients had progressed and 56% had died. The median overall survival (OS) was 16.0 months, and the median progression-free survival (PFS) was 7.1 months. The researchers found no significant associations between age, sex, smoking status, histology, M stage, PD-L1 status, and survival outcomes. However, the data showed that patients with a poor LIPI had a longer PFS and OS compared to those with a good or intermediate LIPI. These findings suggest that first-line pembrolizumab is effective in treating older and less fit patients with NSCLC in a real-world setting. Additionally, pretreatment LIPI was not found to be a prognostic factor for survival in this patient population.

Asset Subtitle

William Mullally

Meta Tag

Speaker William Mullally

Topic Metastatic NSCLC: Immunotherapy - Retrospective

Keywords

pembrolizumab

non-small cell lung cancer

NSCLC

real-world experience

LIPI

survival outcomes

overall survival

progression-free survival

older patients

prognostic factor